Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C31H41ClFNO3
CAS Number:
Molecular Weight:
530.11
UNSPSC Code:
41116107
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
haloperidol
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
Fc1ccc(cc1)C(=O)CCCN2CCC(CC2)(OC(=O)CCCCCCCCC)c3ccc(cc3)Cl
InChI
1S/C31H41ClFNO3/c1-2-3-4-5-6-7-8-11-30(36)37-31(26-14-16-27(32)17-15-26)20-23-34(24-21-31)22-9-10-29(35)25-12-18-28(33)19-13-25/h12-19H,2-11,20-24H2,1H3
InChI key
GUTXTARXLVFHDK-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Haloperidol decanoate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Haloperidol decanoate
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Delphine Charvin et al.
Neurobiology of disease, 29(1), 22-29 (2007-10-02)
Huntington's disease (HD) results from an abnormal polyglutamine extension in the N-terminal region of the huntingtin protein. This mutation causes preferential degeneration of striatal projection neurons. We previously demonstrated, in vitro, that dopaminergic D2 receptor stimulation acted synergistically with mutated
Resolution of haloperidol-induced hyperprolactinemia with aripiprazole.
Raymond A Lorenz et al.
Journal of clinical psychopharmacology, 27(5), 524-525 (2007-09-18)
Lucilene Cardoso et al.
Revista da Escola de Enfermagem da U S P, 43(1), 161-167 (2009-05-15)
Non-compliance with drug-based treatment is a complex and universal phenomenon that develops gradually during psychiatric treatments, and is related to disease aggravation. The purpose of this study was to describe the profile of using a given medication in the clientele